Endocyte Back On Track To File Lead Candidate For EU Conditional Approval This Year
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. biotech, which went public last year, will file EC145 and a companion diagnostic for conditional approval in Europe in platinum-resistant ovarian cancer based on findings from four Phase I and Phase II trials in the third quarter.